Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Lomme, France Clinical Trials

A listing of Lomme, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (6) clinical trials

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Carcinosarcomas (CS) (malignant mixed Mllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) < 10% and a poor prognosis. After initial treatment (surgery +/- adjuvant radiotherapies …

Phase

3.36 miles

Learn More »

Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study

This multicenter, prospective, open-labeled 2-arm, randomized non-comparative phase II trial. This phase II trial is based on a 2-stage Simon's optimal design. Randomization 1:1 with 1 patient randomized in experimental arm A (association of nivolumab plus relatlimab) and 1 patient randomized in arm B (treatment by nivolumab alone).

Phase

3.36 miles

Learn More »

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

In 2014, the International Myeloma Working Group (IMWG) proposed a revised classification of multiple myeloma (MM) and smoldering myeloma (SMM). Since the new definition of SMM proposed excludes "ultra-high risk SMM", the evolution profile of SMM will change. Therefore, investigators need to update their knowledge of SMM to optimize the …

Phase N/A

3.37 miles

Learn More »

Study Association of Lenalidomide Ixazomib Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

This is a phase II, multicenter, non-randomized, open-label study to evaluate the safety and efficacy of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in patients with newly diagnosed multiple myeloma. The patient population will consist of adult men and women 65 years, who have a confirmed diagnosis of standard risk multiple myeloma, …

Phase

3.37 miles

Learn More »

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

First stage : Arm A: Nivolumab + Cyclophosphamide-Vinblastine Arm B: Nivolumab + Capecitabin Arm C: Nivolumab + Cyclophosphamide-Vinblastine + Capecitabin Arm A and Arm B will be initially allocated sequentially (A/B/A/B/A/B). Arm C will be opened, if arm A and Arm B are deemed safe. In each arm, the second …

Phase

3.37 miles

Learn More »

Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Treatment of non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutation is mainly based on tyrosine kinase inhibitors (TKIs) targeting EGFR. 1st or 2nd generation inhibitors have been shown to be superior to chemotherapy in terms of Progression-Free Survival (PFS) when used as 1st line treatment. In …

Phase

3.4 miles

Learn More »